Nuvalent Completes $135 Million Series B Financing To Advance Portfolio Of Novel Precisely Targeted Kinase Inhibitors For Treatment-Resistant Cancers
Nuvalent Completes $135 Million Series B Financing To Advance Portfolio Of Novel Precisely Targeted Kinase Inhibitors For Treatment-Resistant Cancers
05/11/21, 10:09 AM
Location
cambridgeMoney raised
$135 million
Round Type
series b
Nuvalent, Inc., a biotechnology company creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the completion of a $135 million Series B financing. The round was led by Bain Capital Life Sciences with participation from sole founding investor, Deerfield Management, and additional new investors Fidelity Management and Research Company LLC, Wellington Management Company, Viking Global Investors, Janus Henderson Investors, Avoro Capital Advisors, Boxer Capital of Tavistock Group, Venrock Healthcare Capital Partners, Fairmount Funds Management LLC, Driehaus Capital Management LLC, and Logos Capital. Andrew Hack, M.D., Ph.D., a Managing Director of Bain Capital Life Sciences, will join the Nuvalent Board of Directors.
Company Info
Location
cambridge, maryland, united states
Additional Info
Nuvalent, Inc. is creating precisely targeted therapies designed to overcome the limitations of existing therapies for clinically proven kinase targets for patients with cancer. Leveraging deep expertise in structure-based design, Nuvalent develops innovative small molecules with exquisite target selectivity to overcome resistance, minimize adverse events, and drive more durable responses. Nuvalent is advancing a robust pipeline with parallel lead programs in ROS1-positive and ALK-positive NSCLC, along with multiple discovery-stage research programs. To learn more, visit www.nuvalent.com and follow us on Twitter and LinkedIn.
SOURCE Nuvalent, Inc.